Azenta, Inc.

NasdaqGS:AZTA 株式レポート

時価総額：US$738.4m

Azenta 将来の成長

Future 基準チェック /36

Azenta利益と収益がそれぞれ年間95.1%と5%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に0.9% 90.1%なると予測されています。

主要情報

95.1%

収益成長率

90.15%

EPS成長率

Life Sciences 収益成長17.5%
収益成長率5.0%
将来の株主資本利益率0.85%
アナリストカバレッジ

Good

最終更新日08 May 2026

今後の成長に関する最新情報

Recent updates

ナラティブの更新 • May 01

AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery

Azenta's updated analyst price target has moved modestly lower by about $0.77, as analysts factor in refreshed assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E following a series of recent target cuts from major firms. Analyst Commentary Recent Street research has focused on recalibrating Azenta's fair value, with several firms trimming their price targets by between $5 and $10 as they reassess assumptions for growth, profitability, and appropriate P/E levels.
ナラティブの更新 • Apr 15

AZTA: 2026 Guidance And Space Research Will Support Sentiment Recovery

Azenta's analyst price target has been trimmed by about $2.50 as analysts factor in updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E following a series of recent target cuts from major firms. Analyst Commentary Recent Street research on Azenta points to a more cautious tone on valuation, with multiple price target trims clustering over a relatively short period.
ナラティブの更新 • Apr 01

AZTA: 2026 Guidance And Space Research Tests Will Support Sentiment Recovery

Azenta's analyst price targets have been reduced by $5 to $9 in recent updates, as analysts factor in revised expectations for the diagnostic tools group and place greater emphasis on 2026 guidance and the clarity of the company's multi year growth framework. Analyst Commentary Recent research updates on Azenta show a mix of optimism around the long term framework and caution around the nearer term setup, with price targets adjusted both higher and lower as estimates and expectations are refreshed.
Seeking Alpha • Mar 24

Azenta: Life Science Player Fails To Come To Life

Summary Azenta, Inc. trades near $20, with operating assets valued at just 0.5x sales and a robust net cash position around $600 million. Recent AZTA developments include the UK Biocentre acquisition and B Medical Systems divestiture, with the latter removing a key earnings drag. Despite a soft Q1 and margin pressure, Azenta maintains full-year guidance, supported by remediation efforts and interest income. The AZTA risk/reward is compelling at current levels, given low expectations, significant liquidity, and underappreciated asset value, making me a buyer despite above-average risks. Read the full article on Seeking Alpha
ナラティブの更新 • Mar 18

AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery

Azenta's analyst price targets have edged lower by a mid single digit dollar amount to around $39, as analysts factor in updated discount rate and growth assumptions, while still highlighting the importance of 2026 guidance and multi year frameworks for potential upside. Analyst Commentary Bullish Takeaways Bullish analysts point to the move to a US$39 price target as a reflection of clearer multi year planning, which supports their view that the company has several paths to grow into that valuation over time.
ナラティブの更新 • Mar 03

AZTA: 2026 Framework And Buybacks Will Underpin Sentiment Recovery

Narrative Update: Azenta Azenta's latest analyst price targets have shifted slightly lower in recent research updates, with firms trimming their views by $5 and $9 after a prior increase to $39, as analysts factor in group wide adjustments in diagnostic tools and place more weight on visibility into the company's multi year framework and 2026 guidance. Analyst Commentary Recent research updates on Azenta reflect a mix of optimism about the long term setup and caution around execution and visibility, especially as analysts refresh their views on the broader diagnostic tools group and Azenta's multi year framework.
新しいナラティブ • Feb 25

Automation And Biorepositories Will Steadily Support A Fairly Valued Long Term Outlook

Catalysts About Azenta Azenta provides life sciences customers with sample management, biorepositories and multiomics services such as next-generation sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?
ナラティブの更新 • Feb 17

AZTA: 2026 Margin Framework And Buybacks Will Support Future Upside

Analysts have trimmed their average price target on Azenta from about $43.50 to roughly $38.67, reflecting recent target cuts of $5 and $9, along with updated views on revenue growth, margins and a lower future P/E assumption. Analyst Commentary Recent research shows a mixed but detailed set of views around Azenta, with some focusing on long term growth potential and others dialing back expectations on valuation and near term execution.
新しいナラティブ • Feb 08

Multiomics Outsourcing And Automation Will Drive A Powerful Long Term Earnings Shift

Catalysts About Azenta Azenta provides life sciences customers with sample management, multiomics services and automation solutions across biorepositories, sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?
ナラティブの更新 • Feb 03

AZTA: 2026 Margin Path And Buybacks Will Support Upside Potential

Analysts have nudged up their Azenta targets, with one moving to US$39 and another to US$45. This reflects interest in the company’s multi year growth framework and expectations for mid single digit organic revenue trends, with a path to margins above 20%.
ナラティブの更新 • Jan 20

AZTA: Biopharma Exposure And 2026 Margin Path Support Balanced Risk Reward

Analysts have lifted their price target on Azenta to about US$43.50 from roughly US$40.17, citing slightly lower revenue growth expectations, firmer profit margin assumptions and a modestly lower future P/E outlook. The revised target is supported by recent research that notes improving sentiment, mid single digit organic revenue ambitions and a path to higher margins into 2026.
ナラティブの更新 • Jan 05

AZTA: Biopharma Exposure Will Support Margin Expansion And 2026 Re Rating Potential

Analysts have nudged their fair value estimate for Azenta slightly higher to about $40, reflecting updated price targets in the mid to high $30s and low $40s, and their view that organic revenue growth and margin expansion potential into 2026 support a more constructive outlook on the shares. Analyst Commentary Recent research updates highlight a more constructive tone on Azenta, with several firms lifting price targets and turning more positive after the latest fiscal Q4 report and ahead of the upcoming investor day.
ナラティブの更新 • Dec 14

AZTA: Biopharma Exposure Will Support Mid-Single-Digit Growth And Margin Expansion

Azenta's analyst price target has been raised by $10 to $45, as analysts point to mid single digit plus organic revenue growth prospects and a credible path to margins above 20% that is supported by healthy biopharma exposure and multiple growth drivers into 2026. Analyst Commentary Bullish analysts highlight that the latest results, while largely in line with expectations, reinforce confidence in Azenta's ability to sustain mid single digit plus organic revenue growth while steadily expanding margins above 20% over the medium term.
ナラティブの更新 • Nov 29

AZTA: Mid-Single-Digit Organic Revenue Acceleration Will Broaden Profit Margins Into 2026

Azenta's analyst price target has increased from $35.17 to $39.83. Analysts cite in-line financial results and ongoing optimism around revenue growth and expanding profit margins, supported by sector exposure and long-term innovation opportunities.
分析記事 • Nov 28

Azenta's (NASDAQ:AZTA) Earnings Offer More Than Meets The Eye

Investors signalled that they were pleased with Azenta, Inc.'s ( NASDAQ:AZTA ) most recent earnings report. Looking...
ナラティブの更新 • Nov 14

AZTA: Growth Drivers From Biopharma Exposure And Acquisitions Will Unlock Opportunity

Analysts have raised their price target for Azenta from $30 to $38, citing expectations for increased growth opportunities and a positive outlook. This outlook is based on innovation, robust biopharma exposure, and prospective acquisitions.
ナラティブの更新 • Oct 30

AZTA: Biopharma Demand and Acquisition Focus Will Drive Shares Higher Through 2026

Azenta's analyst price target has been raised from $33 to approximately $35.17 per share. Analysts cite increased confidence in the company's growth drivers and mid-term opportunities, particularly within the biopharma sector.
分析記事 • Sep 12

Is There Now An Opportunity In Azenta, Inc. (NASDAQ:AZTA)?

While Azenta, Inc. ( NASDAQ:AZTA ) might not have the largest market cap around , it saw a decent share price growth of...
分析記事 • Aug 07

Azenta, Inc. (NASDAQ:AZTA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

NasdaqGS:AZTA 1 Year Share Price vs Fair Value Explore Azenta's Fair Values from the Community and select yours It's...
分析記事 • Jul 24

Calculating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)

Key Insights Azenta's estimated fair value is US$38.26 based on 2 Stage Free Cash Flow to Equity Current share price of...
User avatar
新しいナラティブ • May 28

Pharma And Biotech Outsourcing Will Shape Future Market Dynamics

Strong industry trends and Azenta's infrastructure investments are driving above-market growth, recurring revenues, and operating leverage in sample management and biobanking.
Seeking Alpha • Apr 17

Azenta: Life Science Business Failing To Come To Life

Summary Azenta, formerly Brooks Automation, has struggled to show organic growth and profitability, leading to a significant drop in its stock price. Despite a strong balance sheet and reduced valuation, the company needs to deliver real margin growth and profitability to attract investors. The company has faced challenges, including a decline in organic sales and the departure of its CEO, but continues to make strategic moves like selling B Medical Systems. Given the compressed sales multiples and strong cash position, a speculative position might be warranted, but management must prove its ability to improve earnings. Read the full article on Seeking Alpha
分析記事 • Apr 05

Azenta, Inc.'s (NASDAQ:AZTA) 29% Share Price Plunge Could Signal Some Risk

Unfortunately for some shareholders, the Azenta, Inc. ( NASDAQ:AZTA ) share price has dived 29% in the last thirty...
分析記事 • Mar 28

Are Investors Undervaluing Azenta, Inc. (NASDAQ:AZTA) By 50%?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Azenta fair value estimate is US$70.94 Current share price of...
Seeking Alpha • Jan 27

Azenta: Taking A Pass

Summary Azenta, Inc. shares have surged over 30% since Nov 2024 due to S&P 600 inclusion and an analyst upgrade, despite somewhat tepid growth prospects. The company is restructuring to save $30-$40 million by FY26, divesting a business segment, and has a strong balance sheet. An analysis on Azenta, Inc. follows in the paragraphs below. Read the full article on Seeking Alpha
分析記事 • Jan 10

At US$51.81, Is Azenta, Inc. (NASDAQ:AZTA) Worth Looking At Closely?

Azenta, Inc. ( NASDAQ:AZTA ), is not the largest company out there, but it received a lot of attention from a...
分析記事 • Dec 20

A Look At The Intrinsic Value Of Azenta, Inc. (NASDAQ:AZTA)

Key Insights The projected fair value for Azenta is US$56.65 based on 2 Stage Free Cash Flow to Equity With US$49.50...
分析記事 • Nov 17

Analysts Have Just Cut Their Azenta, Inc. (NASDAQ:AZTA) Revenue Estimates By 14%

The analysts covering Azenta, Inc. ( NASDAQ:AZTA ) delivered a dose of negativity to shareholders today, by making a...
分析記事 • Nov 14

Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price

It's not a stretch to say that Azenta, Inc.'s ( NASDAQ:AZTA ) price-to-sales (or "P/S") ratio of 3.1x right now seems...
Seeking Alpha • Sep 11

Azenta: Life Science Play Is Not Coming To Life

Summary Azenta, Inc., formerly Brooks Automation, has struggled after the sale of its semiconductor business, as the remaining life sciences business has failed to turn a profit. Following aggressive share buybacks, Azenta's valuation remains demanding, with high earnings multiples and significant discrepancies between GAAP and non-GAAP earnings. New CEO John Marotta brings industry experience, but immediate results are unlikely, as the company needs to improve its margin profile and organic growth. I remain cautious on Azenta, monitoring its progress under new leadership, despite the seemingly low sales multiple and strong revenue base. Read the full article on Seeking Alpha
分析記事 • Jul 19

Azenta, Inc.'s (NASDAQ:AZTA) Shares May Have Run Too Fast Too Soon

When close to half the companies in the Life Sciences industry in the United States have price-to-sales ratios (or...

業績と収益の成長予測

NasdaqGS:AZTA - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
9/30/20286752150904
9/30/20276301741806
9/30/2026600-15940736
3/31/2026596-1113062N/A
12/31/2025595263163N/A
9/30/2025594243872N/A
6/30/2025586-275288N/A
3/31/2025586-283972N/A
12/31/2024579-243266N/A
9/30/2024573-241250N/A
6/30/2024595-212462N/A
3/31/2024616-233169N/A
12/31/2023628-91048N/A
9/30/2023551-8-346N/A
6/30/2023630-21-56-13N/A
3/31/2023597-26-500-449N/A
12/31/2022594-25-581-509N/A
9/30/2022555-11-543-466N/A
6/30/2022555-28-530-449N/A
3/31/2022551-23-5916N/A
12/31/2021535-2966122N/A
9/30/2021514-2997150N/A
6/30/2021114-69130175N/A
3/31/2021205-53112156N/A
12/31/2020296-371056N/A
9/30/2020389-26-238N/A
6/30/202085041-1919N/A
3/31/202083428-729N/A
12/31/201981216N/A110N/A
9/30/2019334-61N/A91N/A
6/30/20197413N/A89N/A
3/31/20197107N/A73N/A
12/31/201866872N/A77N/A
9/30/201863268N/A74N/A
6/30/201848835N/A78N/A
3/31/201849847N/A76N/A
12/31/2017510-2N/A81N/A
9/30/201752711N/A96N/A
6/30/201766956N/A85N/A
3/31/201763447N/A82N/A
12/31/2016600-51N/A71N/A
9/30/2016434-85N/A40N/A
6/30/2016549-73N/A38N/A
3/31/2016546-74N/A39N/A
12/31/201555012N/A28N/A
9/30/201555314N/A44N/A
6/30/20155298N/A35N/A

アナリストによる今後の成長予測

収入対貯蓄率: AZTAは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.5% ) よりも高い成長率であると考えられます。

収益対市場: AZTA今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: AZTA今後 3 年以内に収益を上げることが予想されます。

収益対市場: AZTAの収益 ( 5% ) US市場 ( 11.7% ) よりも低い成長が予測されています。

高い収益成長: AZTAの収益 ( 5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: AZTAの 自己資本利益率 は、3年後には低くなると予測されています ( 0.9 %)。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/18 13:09
終値2026/05/15 00:00
収益2026/03/31
年間収益2025/09/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Azenta, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15

アナリスト機関
Christopher MuseBarclays
Brett HodessBofA Global Research
Paul KnightBrean Capital Historical (Janney Montgomery)